Page last updated: 2024-09-03

pak 104p and EHS Tumor

pak 104p has been researched along with EHS Tumor in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cao, S; Minderman, H; Rustum, YM; Scheper, RJ; Slovak, ML; Tóth, K; Vanhoefer, U1

Other Studies

1 other study(ies) available for pak 104p and EHS Tumor

ArticleYear
PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cyclic P-Oxides; Doxorubicin; Drug Resistance, Neoplasm; Glutathione; Humans; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Transplantation; Nicotinic Acids; Paclitaxel; Sarcoma, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured

1996